KW-6356 (international nonproprietary name sipagladenant) is an oral adenosine A2A receptor antagonist.
Amounts reported for KW-6356 are listed under Reported protocols, each with its source and study kind. No amount ladder is inferred from them. This is educational source context, not a protocol or recommendation.
Enter a target amount only from your own reviewed source. The calculator can convert it into concentration, volume and device markings, but it will not infer an amount from product availability or another compound.
Only mcg or mg amounts are retained. The calculator derives mL, syringe units or pen clicks from the current vial strength, water volume and device.
Human study rows are described per source under Reported protocols; they belong to their trial populations and are not a general amount.
Verify the exact compound, formulation and amount against the product label or certificate before calculation.
Follow the product label, certificate and validated laboratory SOP; no universal storage assumption is applied here.
Label concentration and preparation date, use sterile technique where applicable, and follow a validated stability protocol.
What published studies and recent community write-ups report about amounts, timing and course length. 3 clinical, 1 preclinical and 1 community-reported rows, each linked to its source. These are descriptions of what others report, not instructions, and nothing here is medical advice.
| Context | Dose | Frequency | Route | Course | Source |
|---|---|---|---|---|---|
| Clinical3 rows | |||||
| Phase 2a monotherapy trial in early untreated Parkinson's disease168 Japanese patients with early Parkinson's disease not yet on treatment (NCT02939391) | 3 mg or 6 mg | Once daily in the morning after breakfast | Oral | 12 weeks, with a safety follow-up at week 14None described | Parkinsonism and Related Disorders (PubMed)2023 |
| MDS-UPDRS Part III motor scores fell by 5.37 points on 3 mg and 4.76 on 6 mg against 3.14 on placebo, with the lower dose doing slightly better, and more than 90% of each group completed. The most common adverse events on the drug were constipation (7-10%) and nasopharyngitis (7-9%). The trial was run and co-authored by Kyowa Kirin, and the responsible investigators report fees from the company. | |||||
| Phase 2b adjunct-to-levodopa trial (congress abstract)503 Japanese patients with Parkinson's disease on levodopa, with or without wearing-off (NCT03703570) | 3 mg or 6 mg | Once daily | Oral | 24 weeksNone described | MDS Abstracts, International Congress 20222022 |
| Both doses lowered MDS-UPDRS Part III scores against placebo (p = 0.006 for 3 mg, p = 0.049 for 6 mg) and reduced daily OFF time, and a post-hoc analysis linked 6 mg to better sleep scores. Kyowa Kirin announced in October 2020 that the primary endpoint was met with no major safety issues, but the full results were never published as a paper, and the company ended development in July 2022. | |||||
| Phase 1 single and multiple dose studies in healthy volunteersHealthy Japanese and White adults in two placebo-controlled phase 1 studies | Single doses of 1-60 mg; repeated doses of 6 mg or 24 mg | Once daily for the repeated-dose arms | Oral | 14 days of repeated dosingNot applicable | Clinical Pharmacology in Drug Development (PubMed)2023 |
| KW-6356 was well tolerated up to 60 mg as a single dose and 24 mg a day for two weeks, far above the 3-6 mg used in patients. Exposure rose in proportion to dose, the terminal half-life ranged from 18.4 to 43.1 hours, and there was no clear ethnic difference in safety or pharmacokinetics. The long half-life is what supports once-daily dosing. | |||||
| Preclinical1 row | |||||
| MPTP-lesioned marmosets, alone and with levodopaCommon marmosets with MPTP-induced parkinsonism, some primed to show dyskinesia | Up to 1 mg/kg alone; 1 mg/kg combined with levodopa at 1.25-10 mg/kg | Single doses, and daily for 21 days in the chronic combination experiment | Oral | 21 days in the chronic armNot applicable | European Journal of Pharmacology (PubMed)2023 |
| On its own KW-6356 reversed motor disability dose-dependently up to 1 mg/kg, more strongly than istradefylline, and repeated dosing caused little dyskinesia. Combined with levodopa it enhanced the anti-parkinsonian effect across the levodopa range without adding to dyskinesia at matched doses. Both studies were performed and funded by Kyowa Kirin. | |||||
| Community-reported1 row | |||||
| Vendor liquid format | 5 mg/mL in a 30 mL bottle (150 mg total); no dose stated | Not stated | Oral liquid implied; the trials used oral dosing | Not statedNot stated | Community resource2026 |
| A vendor claim. The product page lists the five Kyowa Kirin papers but gives no amount per administration; the certificate for lot 339DR measured 5.139 mg/mL. One millilitre of this liquid is close to the 6 mg trial dose, and the whole bottle holds about 25-50 days of the doses used in patients. The vendor also describes the compound as a nootropic, a use with no published study. | |||||
Plus 1 community resource (a dosing guide, forum thread or vendor write-up), reported above but not linked.
KW-6356 (international nonproprietary name sipagladenant) is an oral adenosine A2A receptor antagonist and inverse agonist discovered by Kyowa Kirin as a successor to its approved Parkinson's drug istradefylline (Nourianz). In Japanese phase 2 trials it improved motor scores both on its own in early untreated Parkinson's disease, at 3 or 6 mg once daily for 12 weeks, and as an add-on to levodopa over 24 weeks in about 500 patients, with constipation the most common side effect. Kyowa Kirin discontinued the programme in July 2022, citing the global regulatory landscape, development hurdles and time to market rather than any safety finding, so the compound is not approved anywhere and is sold online only as a research chemical.
These themes describe recurring questions in published research. They are not claims of effectiveness or recommendations for use.
Neuroplasticity, cognition, stress and sleep models.
MDS-UPDRS Part III motor scores fell by 5.37 points on 3 mg and 4.76 on 6 mg against 3.14 on placebo, with the lower dose doing slightly better, and more than 90% of each group completed. The most common adverse events.
Both doses lowered MDS-UPDRS Part III scores against placebo (p = 0.006 for 3 mg, p = 0.049 for 6 mg) and reduced daily OFF time, and a post-hoc analysis linked 6 mg to better sleep scores. Kyowa Kirin announced in.
KW-6356 was well tolerated up to 60 mg as a single dose and 24 mg a day for two weeks, far above the 3-6 mg used in patients. Exposure rose in proportion to dose, the terminal half-life ranged from 18.4 to 43.1 hours.
On its own KW-6356 reversed motor disability dose-dependently up to 1 mg/kg, more strongly than istradefylline, and repeated dosing caused little dyskinesia. Combined with levodopa it enhanced the anti-parkinsonian.
A vendor claim. The product page lists the five Kyowa Kirin papers but gives no amount per administration; the certificate for lot 339DR measured 5.139 mg/mL. One millilitre of this liquid is close to the 6 mg trial.
Study models remain visible so laboratory and animal findings are not mistaken for established human outcomes.
3 protocol rows on this page come from human trials, trial registrations, regulator labels or reviews of human data. Approval status and populations are stated per row.
1 protocol row describe animal, cell or toxicology work. Amounts from these rows do not translate to people.
1 row record what blogs, vendor write-ups or forums describe for KW-6356. None has been verified against primary literature.
Sequence, synonyms and registry identifiers as recorded in PubChem, the National Library of Medicine's open chemistry database. Formula, mass and CAS number are summarized at the top of the page.
Sipagladenant, KW-6356, KW6356, Sipagladenant [INN], UNII FF2012ZV92, CHEMBL5314441
KMFLQPJJHQNKKF-UHFFFAOYSA-N
N-[4-(furan-2-yl)-5-(oxane-4-carbonyl)-1,3-thiazol-2-yl]-6-methylpyridine-3-carboxamide
8 curated references, each with its journal, year and study model, plus 1 community resource reported but not linked.